Novel Dry Eye Pharmaceuticals Are Changing MGD Care

2 novel pharmaceutical treatments are showing promise for relieving dry eye disease (DED) symptoms — the first addressing DED due to Demodex ...

Optometry Advisor on LinkedIn: Novel Dry Eye Pharmaceuticals Are ...

... pharmaceutical treatments have the potential to change the paradigm for treating #DryEyeDisease. #MeibomianGlandDysfunction (MGD) has a ...

What's New and What's Coming in OSD Treatment

1. Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and ...

Dry Eye Drugs: What's New and What's Next - Review of Optometry

Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Alcon). This corticosteroid eye drop is used for the treatment of DED flares. In ...

Investigating a novel therapeutic composition for dry eye syndrome ...

The primary approach to the management of DES involves using over-the-counter artificial tears and ocular lubricants; however, their frequent ...

Bausch + Lomb Exec Discusses Novel Dry Eye Disease Treatment

The FDA recently granted approval of Bausch + Lomb's Miebo (perfluorohexyloctane ophthalmic solution), the first and only FDA-approved ...

Recent United States Developments in the Pharmacological ...

Abstract. Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), ...

Clinical Challenges: Will New Prescription Eye Drop Change DED ...

John Sheppard, MD, of Virginia Eye Consultants in Norfolk, believes the perfluorohexyloctane eye drops will "shift the dry eye treatment ...

FOUR NOVEL APPROACHES TO DED TREATMENT

This led to the approval of Eysuvis (loteprednol etabonate ophthalmic suspension, 0.25%, Kala Pharmaceuticals) in late 2020. With a novel mucus- ...

Improved Dry Eye Drugs for 2022 and Beyond

New dry eye treatments may be more effective than existing ones ... For patients frustrated with their current treatment options, hope is on the ...

Novel drug delivery systems for the management of dry eye

Artificial tear products are ocular lubricating eye drops used as the first line of treatment for irritation and dryness associated with tear deficient DED. The ...

Advances in Dry Eye Disease Treatment - PMC - PubMed Central

Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures ...

FDA Issues Complete Response for Novel Dry Eye Therapy

Regulatory officials indicated that the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes and requested the ...

2023 Pipeline Drugs Show Promise for Treating Dry Eye Disease

Reproxalap (Aldeyra Therapeutics, Lexington, MA) is another DED medication working its way through the approval process. A novel reactive ...

Dry-Eye Treatments Continue to Evolve - Review of Ophthalmology

Over-the-counter approaches to MGD including heating masks along with the eyelid hygiene. There are several products available over the counter ...

Managing Dry Eye Disease with Novel Medications - MDPI

Non-prescription artificial tears made from ingredients such as carboxymethylcellulose are a common treatment for ADDE. These products provide lubrication to ...

2023 New Treatments for Dry Eyes in LA - iLux²® - BlephEx® - IPL

Not only is iLux technology safe to use for the diagnosis and treatment of MGD, but the tear film breakup time has been found to improve by more than 50% within ...

Peering into the Dry Eye Pipeline for 2023 and Beyond

Novaliq ANNOUNCES FDA approval of VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease ...

MGrx - A Novel Multi-modal Thermal Device for Treating Moderate to ...

A single 15-minute MGrx treatment was effective at significantly improving dry eye symptoms secondary to MGD in adult patients, as measured by SPEED score.

A Look at the Dry-Eye Treatment Pipeline - Review of Ophthalmology

This agent uses a novel, multimodal action that targets inflammation, corneal/conjunctival damage, tear deficiency, and gland tissue ...